Illumina Oncology - Testing for 𝘕𝘛𝘙𝘒 fusions

Опубликовано: 14 Ноябрь 2022
на канале: Illumina

978

Vivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next-generation-sequencing-based testing for NTRK gene fusions. He presents the case of a patient who benefited from precision medicine based on the detection of an NTRK1 fusion by comprehensive genomic profiling.

Dr. Subbiah is the medical director of the Clinical Center for Targeted Therapy and executive director of Oncology Research at the University of Texas MD Anderson Cancer Network.

Listen to the podcast episode to learn more about when to test for NTRK fusions: https://www.illumina.com/science/geno...

Learn about Homologous Recombination Deficiency (HRD) testing in ovarian cancer:    • Illumina Oncology - Homologous Recomb...

The Illumina Oncology series is brought to you by Medical Affairs.

M-GL-01113

Subscribe to the Illumina video channel http://www.youtube.com/subscription_c...

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos
   • Illumina Customer Testimonials

View Illumina webinars
   • Webinars

View Illumina product videos
   • Playlist

View Illumina support videos
   • Illumina Support

Facebook:   / illuminainc
LinkedIn:   / illumina
Instagram:   / illuminainc
Twitter:   / illumina